These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22073867)

  • 1. [Microinflammation in diabetic nephropathy].
    Ogawa D; Shikata K
    Nihon Jinzo Gakkai Shi; 2011; 53(7):1021-6. PubMed ID: 22073867
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of oxidative stress in pathogenesis of diabetic nephropathy].
    Inoguchi T
    Nihon Jinzo Gakkai Shi; 2011; 53(7):1016-20. PubMed ID: 22073866
    [No Abstract]   [Full Text] [Related]  

  • 3. [Microinflammation in the pathogenesis of diabetic nephropathy].
    Shikata K
    Nihon Jinzo Gakkai Shi; 2007; 49(5):474-80. PubMed ID: 17695807
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of chemokines/chemokine receptors in pathogenesis of diabetic nephropathy].
    Hara A; Wada T
    Nihon Jinzo Gakkai Shi; 2011; 53(7):1027-33. PubMed ID: 22073868
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic nephropathy: causes and managements.
    Tripathi YB; Yadav D
    Recent Pat Endocr Metab Immune Drug Discov; 2013 Jan; 7(1):57-64. PubMed ID: 23227864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The protective role of PPARgamma in diabetic nephropathy].
    Zang HL; Wang CJ; Yang JC
    Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):435-8. PubMed ID: 21416961
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sirt1 in diabetic nephropathy].
    Kume S; Koya D; Maegawa H
    Nihon Jinzo Gakkai Shi; 2011; 53(7):1010-5. PubMed ID: 22073865
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prevention and remission of diabetic nephropathy].
    Sugimoto T; Nakamura Y; Makino H
    Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin resistance on endothelial progenitor cells and vascular repair.
    Cubbon RM; Kahn MB; Wheatcroft SB
    Clin Sci (Lond); 2009 Aug; 117(5):173-90. PubMed ID: 19630751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiology patient page. The metabolic syndrome.
    Lennie TA
    Circulation; 2006 Oct; 114(15):e528-9. PubMed ID: 17030691
    [No Abstract]   [Full Text] [Related]  

  • 12. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease.
    Casey RG; Joyce M; Roche-Nagle G; Chen G; Bouchier-Hayes D
    J Surg Res; 2005 Feb; 123(2):176-81. PubMed ID: 15680375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome.
    Pakala R; Kuchulakanti P; Rha SW; Cheneau E; Baffour R; Waksman R
    Cardiovasc Radiat Med; 2004; 5(2):97-103. PubMed ID: 15464947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on nephrology].
    Imai E; Hamano T
    Nihon Jinzo Gakkai Shi; 2010; 52(1):13-27. PubMed ID: 20166535
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
    Nezami N; Safa J; Eftekhar-Sadat AT; Salari B; Ghorashi S; Sakhaee K; Khosraviani K
    Clin Biochem; 2010 Nov; 43(16-17):1294-9. PubMed ID: 20727867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel therapeutic approaches to diabetic nephropathy].
    Miyata T
    Nihon Jinzo Gakkai Shi; 2007; 49(5):491-5. PubMed ID: 17695810
    [No Abstract]   [Full Text] [Related]  

  • 19. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.
    Koh KK; Han SH; Quon MJ
    J Am Coll Cardiol; 2005 Dec; 46(11):1978-85. PubMed ID: 16325028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.